切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2015, Vol. 03 ›› Issue (03) : 144 -147. doi: 10.3877/cma.j.issn.2095-5782.2015.03.008

所属专题: 文献

肿瘤介入

125I粒子条植入治疗原发性肝癌伴门静脉主干癌栓的近期疗效
武京鹏1, 何东风1,()   
  1. 1. 150081 哈尔滨医科大学附属肿瘤医院介入科
  • 收稿日期:2014-07-04 出版日期:2015-08-01
  • 通信作者: 何东风
  • 基金资助:
    黑龙江省科技厅青年自然科技基金(QC08C06)

Evaluation the efficacy of 125I seed strand implantation for treatment of hepatocellular carcinoma with main portal vein tumor thrombus

Jingpeng Wu1, Dongfeng He1,()   

  1. 1. Department of Interventional Therapy, The Affiliated Tumor Hospital of Harbin Medical University, Harbin 150081, China
  • Received:2014-07-04 Published:2015-08-01
  • Corresponding author: Dongfeng He
  • About author:
    Corresponding author: He Dongfeng, Email:
引用本文:

武京鹏, 何东风. 125I粒子条植入治疗原发性肝癌伴门静脉主干癌栓的近期疗效[J/OL]. 中华介入放射学电子杂志, 2015, 03(03): 144-147.

Jingpeng Wu, Dongfeng He. Evaluation the efficacy of 125I seed strand implantation for treatment of hepatocellular carcinoma with main portal vein tumor thrombus[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2015, 03(03): 144-147.

目的

探讨125I粒子条植入治疗原发性肝癌伴门静脉主干癌栓的安全性及近期疗效。

方法

15例原发性肝癌伴门静脉主干癌栓患者行门静脉125I粒子条植入术,手术操作在超声及DSA引导下进行。术后对肝功能、血常规及凝血功能的变化、癌栓的改变、不良反应进行评价。

结果

所有患者均成功植入放射性125I粒子条,门静脉主干癌栓的有效率为40.00%(6/15),疾病控制率为86.67%(13/15)。术后2个月复查所有患者的肝功能、血常规、凝血功能与术前比较差异无统计学意义。未出现与粒子条植入相关的严重并发症。

结论

植入125I粒子条治疗肝癌伴门静脉主干癌栓是安全、可行、有效的。

Objective

To discuss the therapeutic efficacy and safety of 125I seed strand implantation for treatment of hepatocellular carcinoma (HCC) with main portal vein tumor thrombus (MPVTT).

Methods

A total of 15 patients with confirmed HCC accompanied by MPVTT received implantation of 125I seed strand via portal vein. The procedure was guided by ultrasound and DSA. The hepatic function, routine blood test as well as coagulation function, the changes of PVTT and the postoperative complications were analyzed.

Results

The implantation of 125I seed strand was successfully accomplished in all the patients. The objective response rate of MPVTT was 40.00% (6/15) and the disease control rate was 86.67% (13/15). There was no significant difference between preoperative and postoperative two months in hepatic function, routine blood test and coagulation function. No serious procedure-related complications occurred.

Conclusions

Implantation of 125I seed strand is safe, feasible and effective to treat MPVTT in HCC.

表1 患者的一般临床资料
表2 患者术前、术后实验室指标变化(±s
1
Llovet JM, Bruix J. Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma[J]. Hepatology, 2000,32(3):679-680.
2
Park KW, Park JW, Choi JI, et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area[J]. J Gastroenterol Hepatol, 2008,23(3):467-473.
3
Li SH, Wei W, Guo RP, et al. Long-term outcomes after curative resection for patients with macroscopically solitary hepatocellular carcinoma without macrovascular invasion and an analysis of prognostic factors[J]. Med Oncol, 2013,30(4):696.
4
Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials[J]. Hepatology, 1999,29(1):62-67.
5
Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival[J]. Hepatology, 2000,32(2):233-238.
6
Katagiri S, Yamamoto M. Multidisciplinary treatments for hepatocellular carcinoma with major portal vein tumor thrombus[J]. Surg Today, 2014,44(2):219-226.
7
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010,30(1):52-60.
8
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008,359(4):378-390.
9
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011,53(3):1020-1022.
10
Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus[J]. World J Gastroenterol, 2006,12(47):7561-7567.
11
Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study[J]. Ann Surg Oncol, 2011,18(2):413-420.
12
Xue TC, Xie XY, Zhang L, et al. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis[J]. BMC Gastroenterol, 2013,13:60.
13
Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes[J]. Gastroenterology, 2010,138(1):52-64.
14
Lau WY, Sangro B, Chen PJ, et al. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90[J]. Oncology, 2013,84(5):311-318.
15
Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes[J]. Int J Radiat Oncol Biol Phys, 2012,82(5):2004-2011.
16
Koo JE, Kim JH, Lim YS, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus[J]. Int J Radiat Oncol Biol Phys, 2010,78(1):180-187.
17
Lee DS, Seong J. Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis[J]. Liver Cancer, 2014,3(1):18-30.
18
广东省抗癌协会肝癌专业委员会,广东省医学会肝胆胰外科学分会.肝细胞肝癌合并门静脉癌栓多学科团队综合治疗广东专家共识(2015版)[J]. 中华消化外科杂志,2015,14(9):694-701.
19
Nickers P, Thissen B, Jansen N, et al. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view[J]. Radiother Oncol, 2006,78(1):47-52.
20
Li W, Guan J, Yang L, et al. Iodine-125 brachytherapy improved overall survival of patients with inoperable stage III/IV non-small cell lung cancer versus the conventional radiotherapy[J]. Med Oncol, 2015,32(1):395.
21
Stannard C, Maree G, Tovey S, et al. Iodine-125 brachytherapy in the management of squamous cell carcinoma of the oral cavity and oropharynx[J]. Brachytherapy, 2014,13(4):405-412.
22
Huang MW, Liu SM, Zheng L, et al. A digital model individual template and CT-guided 125I seed implants for malignant tumors of the head and neck[J]. J Radiat Res, 2012,53(6):973-977.
23
Korinthenberg R, Neuburger D, Nikkhah G, et al. Assessing quality of life in long-term survivors after (1)(2)(5)I brachytherapy for low-grade glioma in childhood[J]. Neuropediatrics, 2011,42(3):110-115.
24
Rombouts SJ, Vogel JA, van Santvoort HC, et al. Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer[J]. Br J Surg, 2015,102(3):182-193.
25
Perez BA, Mettu P, Vajzovic L, et al. Uveal melanoma treated with iodine-125 episcleral plaque: an analysis of dose on disease control and visual outcomes[J]. Int J Radiat Oncol Biol Phys, 2014,89(1):127-136.
26
Shah NV, Houston SK, Markoe A, et al. Combination therapy with triamcinolone acetonide and bevacizumab for the treatment of severe radiation maculopathy in patients with posterior uveal melanoma[J]. Clin Ophthalmol, 2013,7:1877-1882.
27
Zhang W, Yan Z, Luo J, et al. Iodine-125 seeds strand for treatment of tumor thrombus in inferior vena cava: an experimental study in a rabbit model[J]. Cardiovasc Intervent Radiol, 2013,36(5):1371-1382.
28
Luo JJ, Zhang ZH, Liu QX, et al. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus[J]. Hepatol Int, 2016,10(1):185-195.
29
Liu Y, Liu R, Wang P, et al. Percutaneous implantation of (125)iodine seeds for treatment of portal vein tumor thrombosis in hepatocellular carcinoma[J]. Med Oncol, 2015,32(8):214.
[1] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[2] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[3] 赖全友, 高远, 汪建林, 屈士斌, 魏丹, 彭伟. 三维重建技术结合腹腔镜精准肝切除术对肝癌患者术后CD4+、CD8+及免疫球蛋白水平的影响[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 651-654.
[4] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[5] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[6] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[7] 吴雪云, 胡小军, 范应方. 肝切除术中剩余肝再生能力的评估与预测[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 894-897.
[8] 林小勇, 张兰霞, 曾庆劲, 贺需旗, 谭雷, 郭光辉, 龙颖琳, 李凯, 吴宇轩. 负压抽吸活检针在肝困难病灶活检中的初步应用研究[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 694-698.
[9] 雷永琪, 刘新阳, 杨黎渝, 铁学宏, 俞星新, 耿志达, 刘雨, 陈政良, 惠鹏, 梁英健. 肝脏血管周上皮样细胞肿瘤合并贫血一例并文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 710-718.
[10] 欧阳佳裕, 李刚, 贺露瑶, 罗娜. 双层探测器光谱CT在早期原发性肝癌中的诊断价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(04): 557-561.
[11] 王凯飞, 牟怡平, 李晓辉, 王瑞涛, 侯惠莲, 张月浪. 原发性肝平滑肌肉瘤临床病理特征及疗效分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 357-362.
[12] 陈志坚, 俞建达, 池小斌, 吕立志, 陈永标. 三维可视化技术在腹腔镜肝巨大肿瘤切除中的应用价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 302-307.
[13] 黄俊豪, 陈宗杰, 胡添松. 血小板相关参数对肝内胆管细胞癌根治性切除患者预后预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 308-312.
[14] 马欢欢, 马晨辉, 邓小博, 王博方, 何普毅, 王云鹏, 许博, 俞荣, 王娜, 陈昊. 肝癌实体瘤治疗疗效评价系统的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 377-383.
[15] 张婵, 吕瑶, 张小燕, 张鸣青. 不同时机局部神经阻滞在开腹肝切除中的镇痛效果比较[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 189-194.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?